Original price was: €703.68.€598.08Current price is: €598.08.
Original price was: €703.68.€598.08Current price is: €598.08.
Reta (LY-3437943) is an investigational peptide for the treatment of obesity and type 2 diabetes. It acts as a triple receptor agonist, targeting the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and glucagon. This complex approach is designed to manage blood sugar levels and aid weight loss more effectively than drugs that act on a single receptor.
The mechanism of action of Reta involves several key pathways. First, GLP-1, a hormone produced after a meal, stimulates insulin secretion from the pancreas, which is key to regulating blood sugar levels and affecting weight. It slows gastric emptying, making individuals feel full longer, and reduces appetite by acting on hunger centers in the brain. Second, GIP, another incretin hormone similar to GLP-1, also promotes insulin release after meals, contributing to slower gastric emptying and reduced appetite. Finally, glucagon, produced in the pancreas, helps regulate blood glucose levels by converting stored glycogen into glucose when levels drop, which can help with weight management by targeting fat stores for energy.
RETA 5mg: stands out because of its triple agonist nature, promising greater efficacy in weight reduction and diabetes management compared to dual or single agonists. Clinical trials have shown impressive weight loss results, suggesting that retatrutide could be a significant advance in the treatment of obesity and type 2 diabetes.
More detailed information can be found at the following sources: betterweighmedical.com, Wikipedia and valhallavitality.com.
The substance is not a food product or dietary supplement, it is not suitable for human consumption. The product is classified as a chemical reagent approved for marketing in the European Union, and can only be used for scientific research.
| 5 star | 0% | |
| 4 star | 0% | |
| 3 star | 0% | |
| 2 star | 0% | |
| 1 star | 0% |
Sorry, no reviews match your current selections
Reta (LY-3437943) is an investigational peptide for the treatment of obesity and type 2 diabetes. It acts as a triple receptor agonist, targeting the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and glucagon. This complex approach is designed to manage blood sugar levels and aid weight loss more effectively than drugs that act on a single receptor.
€124.48
Retatrutide (LY-3437943) is an investigational peptide for the treatment of obesity and type 2 diabetes. It acts as a triple receptor agonist, targeting the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) and glucagon. This complex approach is designed to manage blood sugar levels and aid weight loss more effectively than drugs that act on a single receptor.
€188.48
Cagri acts as an innovative long-acting amylin analog that activates both amylin and calcitonin receptors. Its uniqueness lies in its ability to trigger a satiety signal in the brain, affecting areas of the brain responsible for both homeostasis and enjoyment of food. Through this mechanism, cagri has the potential to reduce food intake and promote weight loss for patients. In addition, its long-lasting effect allows application once a week, which is convenient for patients
€223.68
Tirz is an antidiabetic peptide used to treat type 2 diabetes and to promote weight loss. It is administered by subcutaneous injection. Tirz acts on two types of receptors: GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic peptide). Both of these hormones are involved in blood sugar control and are secreted by intestinal cells after food consumption, leading to insulin secretion. Tirz as a long-acting GIP analog activates both of these receptors, leading to improved glycemic control【14†source】.
€255.68
We take pride in treating every customer, big or small, with the utmost respect.
Receive a 10% discount on your first purchases.
© 2024 Peptideeurope.eu All Rights Reserved.
All products on this site are for research and development purposes only. The products are not intended for human consumption.
The statements made on this page have not been evaluated by the US Food and Drug Administration. Food and Drug Administration. The statements and products of this company are not intended to diagnose, treat or prevent any disease.
